Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
3/27/2007 1:07:26 PM
More...
|
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President Of Clinical Development
10/24/2006 11:09:14 AM
More...
|
Acuity Pharmaceuticals Reports Positive Phase II Results For Bevasiranib In Wet AMD
9/11/2006 8:15:38 AM
More...
|
Acuity Pharmaceuticals And Pathogenics Inc. Announce Preclinical Data Demonstrating Utility Of NCT In Viral Conjunctivitis
8/23/2006 9:08:26 AM
More...
|
Acuity Pharmaceuticals Reports Positive Initial Phase II Results For Bevasiranib (Cand5) In Wet AMD
6/1/2006 11:02:33 AM
More...
|
ZaBeCor Pharmaceutical Co. Licenses Its Anti-Inflammatory siRNA Technology To Acuity Pharmaceuticals For Ophthalmic Uses
4/28/2006 10:41:51 AM
More...
|
Acuity Pharmaceuticals Continues Pipeline Expansion By Licensing A Novel Broad Spectrum Anti-Infective For Ophthalmic Use
4/20/2006 11:22:32 AM
More...
|
Acuity Pharmaceuticals Completes Patient Enrollment In Phase II Trial In Wet AMD And Initiates New Trial In Diabetic Macular Edema
2/2/2006 10:39:19 AM
More...
|
Acuity Pharmaceuticals To Present At Rodman & Renshaw Healthcare Conference
11/4/2005 12:59:46 PM
More...
|
Acuity Pharmaceuticals Initiates Phase II Trial Of Cand5 In Wet AMD Following Successful Completion Of Phase I
10/19/2005 5:13:21 PM
More...
|
|